Mar 11, 2019 / 04:00PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD and Senior Research Analyst
Good afternoon. We're very, very happy to have Eli Lilly back at the Cowen Conference. Joining us for this conference is Josh Smiley, who is Executive Vice President and Chief Financial Officer.
Before we start the Q&A and please chime in with questions anywhere along the line. I'd just like to note that Lilly has been one of Cowen's longest-standing recommended stocks. We upgraded this stock in April of 2014, so nearly 5 years, and we believe it's as compelling now as any time in that 5-year period because we like the new product story, we like the financial outlook, we like the fact that management consistently delivers. And we like the fact that over decades, Lilly has that creative spark that we can look forward to it bringing an innovative pipeline into the future. We don't think many companies have that, Lilly does, and that we find very appealing.
So with that, Josh, thanks for coming.
Joshua L. Smiley - Eli Lilly and Company - Senior VP & CFO<
Eli Lilly and Co at Cowen Health Care Conference Transcript
Mar 11, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers